Approved indications
Yupelri is approved for long-term, once-daily maintenance treatment of airflow obstruction in adults with COPD, including chronic bronchitis and/or emphysema, and is not for the relief of acute bronchospasm.

Off-label uses
Clinically meaningful off-label uses are limited; it is generally not used in asthma or in children because safety and effectiveness in these groups have not been established, and evidence outside COPD is sparse.

Efficacy expectations
In clinical trials, many patients had improved lung function (measured by FEV1) within hours of the first dose, with benefits maintained over 24 hours and sustained over weeks to months when taken daily. Patients often notice easier breathing, reduced breathlessness with activity, and may have fewer COPD flare-ups when used as part of a full COPD regimen.

Comparison with similar drugs
Yupelri works similarly to other LAMA inhalers (such as tiotropium or umeclidinium) but is delivered by nebulizer once daily, which may be helpful for people who cannot use handheld inhalers effectively; overall efficacy for lung-function improvement is generally comparable within the LAMA class.

Typical dosing
The standard adult dose for COPD is one 175 mcg (3 mL) unit-dose vial of Yupelri inhalation solution administered once daily via a compatible nebulizer. It is a maintenance medication and should be used every day at about the same time, with or without food.

How to take
Use only with a jet nebulizer system that is compatible with Yupelri and includes an appropriate compressor, following the device’s instructions. Open the foil pouch just before use, squeeze the full contents of one vial into the nebulizer cup, and inhale the mist calmly and deeply until the nebulizer stops producing mist. Do not swallow the solution and do not mix it with other nebulized medicines unless your clinician specifically tells you to.

Special instructions
Do not use Yupelri to treat sudden breathing problems; a short-acting rescue inhaler should be used for acute symptoms. Do not exceed the prescribed once-daily dosing, and do not stop using it suddenly without consulting your healthcare provider, as COPD symptoms may worsen.

Missed dose
If a dose is missed, take it as soon as you remember on the same day; if it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not take extra doses to make up for a missed one.

Overdose
Signs of overdose may include severe dry mouth, blurred vision, fast heartbeat, difficulty urinating, or severe dizziness or confusion, and could worsen breathing; in case of suspected overdose, seek emergency medical care or contact poison control right away and bring the medication container with you.

Common side effects
Common side effects include cough, runny or stuffy nose, upper respiratory infections, headache, and sometimes dry mouth or sore throat; these are usually mild to moderate and often appear within the first days to weeks of treatment.

Serious or rare adverse effects
Serious reactions can include paradoxical bronchospasm (worsening breathing right after use), new or worsening glaucoma symptoms (eye pain, blurred vision, halos, or red eyes), urinary retention (trouble urinating, painful urination, or weak urine stream), and severe allergic reactions (rash, swelling of face or throat, difficulty breathing). These require immediate medical attention and stopping the medicine until evaluated.

Warnings and precautions
Use with caution in people with narrow-angle glaucoma, enlarged prostate, or bladder outlet obstruction, as anticholinergic effects can worsen these conditions. It is not indicated for children. For pregnancy and breastfeeding, data in humans are limited; the drug should be used only if the expected benefit justifies potential risks, after discussion with a clinician. Patients with severe kidney or liver disease should be closely monitored because drug exposure may be higher.

Overall safety profile
As a LAMA, Yupelri’s safety profile is generally similar to other inhaled anticholinergic COPD therapies, with mostly mild respiratory and anticholinergic side effects and rare but important eye and urinary events when used appropriately.

Reporting and safety updates
Patients and caregivers can report side effects to the FDA’s MedWatch program or to the manufacturer’s patient safety line, and they can check the FDA’s online drug safety pages for any new warnings or safety communications regarding revefenacin.

Drug and supplement interactions
Using Yupelri with other anticholinergic medicines (such as some bladder control drugs, certain antihistamines, or other LAMA inhalers) can increase side effects like dry mouth, constipation, glaucoma symptoms, or urinary retention. Most other COPD drugs, including inhaled corticosteroids and long- or short-acting beta-agonists, are commonly used together with Yupelri, but the regimen should be reviewed by a clinician. There are no major food interactions known, and alcohol does not have a specific direct interaction, though excessive alcohol can worsen overall breathing and safety.

Other products and procedures
Over-the-counter cold and allergy medicines that contain anticholinergic or sedating antihistamines can add to dry mouth, blurred vision, or urinary difficulties. There are no specific interactions with routine imaging or lab tests, but always inform healthcare providers that you use an inhaled LAMA.

Precautions and conditions
Extra caution is advised in patients with narrow-angle glaucoma, enlarged prostate, bladder outflow obstruction, or a history of urinary retention, as well as in those with severe kidney or liver disease. It should not be used as a rescue medication for acute bronchospasm and should not be started or continued in people with a known severe allergy to revefenacin or any component of the formulation.

Monitoring needs
Routine blood tests are not usually required for Yupelri alone, but clinicians will monitor COPD symptoms, lung function, and any eye or urinary symptoms at follow-up visits. Patients should promptly report vision changes, eye pain, difficulty urinating, or sudden worsening of breathing so treatment can be adjusted.

Q: Is Yupelri a rescue inhaler for sudden shortness of breath?
A: No, Yupelri is a long-acting maintenance medicine taken once daily to help keep airways open over time and should not be used to treat sudden breathing problems; a short-acting rescue inhaler is needed for acute attacks.

Q: How long does it take for Yupelri to start working?
A: Some people may notice easier breathing within hours of the first dose, but full benefits typically develop over several days to weeks of regular daily use.

Q: Can Yupelri be used with my other COPD inhalers?
A: Yupelri is often used together with other COPD medications like inhaled corticosteroids and long- or short-acting bronchodilators, but combining it with other anticholinergic inhalers is usually avoided, so your full regimen should be reviewed by your clinician.

Q: What if I have trouble using handheld inhalers?
A: Yupelri is delivered by nebulizer as a fine mist you breathe in through a mouthpiece or mask, which can be easier for people who have difficulty coordinating sprays or using dry-powder inhalers.

Q: Is Yupelri safe in pregnancy or while breastfeeding?
A: Human data are limited, so Yupelri should only be used in pregnancy or during breastfeeding if the expected benefits outweigh potential risks, after a careful discussion with your healthcare provider.

Storage
Store Yupelri unit-dose vials in the original foil pouch at room temperature, protect from light, and keep them in a dry place; do not freeze, and keep out of reach of children and pets.

Handling and use
Only open a vial immediately before use, do not mix Yupelri with other medicines in the nebulizer unless instructed by a clinician, and discard any opened or unused solution left in the nebulizer cup after each treatment.

Disposal
Discard used vials, packaging, and nebulizer cups in household trash away from children and pets; for large quantities or questions about disposal, consult a pharmacist or local waste-disposal guidelines.